<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table cellspacing="0" cellpadding="2" border="0" id="schedule" style="WIDTH: 643px" summary="This table shows the date, time, and location of the meeting"&gt;     &lt;tbody&gt;         &lt;tr&gt;             &lt;th bgcolor="#cccccc" align="left" valign="top" id="a1" style="WIDTH: 71px"&gt;Center&lt;/th&gt;             &lt;th bgcolor="#cccccc" align="left" valign="top" id="a2" style="WIDTH: 158px"&gt;Date&lt;/th&gt;             &lt;th bgcolor="#cccccc" align="left" valign="top" id="a3" style="WIDTH: 172px"&gt;Time&lt;/th&gt;             &lt;th bgcolor="#cccccc" align="left" valign="top" id="a4" style="WIDTH: 238px"&gt;Location&lt;/th&gt;         &lt;/tr&gt;         &lt;tr&gt;             &lt;td valign="top" height="61" style="WIDTH: 71px" headers="a1"&gt;CDER&lt;/td&gt;             &lt;td valign="top" style="WIDTH: 158px" headers="a2"&gt;April 5, 2012&lt;br /&gt;             &amp;nbsp;&lt;/td&gt;             &lt;td valign="top" style="WIDTH: 172px" headers="a3"&gt;8:00 a.m. to 4:30  p.m.&lt;br /&gt;             &lt;br /&gt;             &amp;nbsp;&lt;/td&gt;             &lt;td valign="top" style="WIDTH: 238px" headers="a4"&gt;FDA White Oak Campus&lt;br /&gt;             Building 31&lt;br /&gt;             The Great Room (Rm. 1503)&lt;br /&gt;             White Oak Conference Center&lt;br /&gt;             10903 New Hampshire Avenue&lt;br /&gt;             Silver Spring, Maryland&lt;/td&gt;         &lt;/tr&gt;     &lt;/tbody&gt; &lt;/table&gt; &lt;p&gt;&amp;nbsp;&lt;/p&gt; &lt;h4&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;/h4&gt; &lt;p&gt;The Committee will discuss the benefits and risks of mirabegron (YM178), under New Drug Application (NDA) 202611, submitted by Astellas Pharma Global Development Inc. for the proposed indication of treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.  Mirabegron is a beta-3-adrenoceptor (AR) agonist and is a new molecular entity. The benefit/risk discussion will focus on the adequacy of the demonstration of efficacy and safety in the treatment of OAB.&lt;/p&gt; &lt;h4&gt;Meeting Materials&lt;/h4&gt; &lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt; &lt;h4&gt;Background Material&lt;/h4&gt; &lt;ul&gt;     &lt;li&gt;&lt;a href="[!--$wcmUrl('link','UCM279865')--]" target=""&gt;2012 Meeting Materials, Reproductive Health Drugs Advisory  Committee&lt;/a&gt;&lt;/li&gt; &lt;/ul&gt; &lt;h4&gt;Public Participation Information&lt;/h4&gt; &lt;p&gt;Interested persons may present data, information, or views, orally or in  writing, on issues pending before the committee.&lt;/p&gt; &lt;ul&gt;     &lt;li&gt;Written submissions may be made to the contact person on or before March 22, 2012.&lt;/li&gt;     &lt;li&gt;Oral presentations from the public will be scheduled between approximately 1            p.m. and 2 p.m. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before March 14, 2012.&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;Time allotted for each presentation may be limited.  If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.  The contact person will notify interested persons regarding their request to speak by March 15, 2012.&lt;/p&gt; &lt;h4&gt;Webcast Information&lt;/h4&gt; &lt;p&gt;CDER plans to provide a free of charge, live webcast of the April 5, 2012, Advisory Committee for Reproductive Health Drugs Meeting.  While CDER is working to make webcasts available to the public for all advisory committee meetings held at the White Oak campus, there are instances where the webcast transmission is not successful; staff will work to re-establish the transmission as soon as possible.  Further information regarding the webcast, including the web address for the webcast, will be made available at least 2 days in advance of the meeting at the following website: &lt;a target="" href="[!--$wcmUrl('link','UCM279865')--]"&gt;2012 Meeting Materials, Advisory Committee for Reproductive Health Drugs&lt;/a&gt;.   CDER plans to post archived webcasts after the meeting, however, in cases where transmission was not successful, archived webcasts will not be available.&lt;/p&gt; &lt;h4&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/h4&gt; &lt;ul&gt;     &lt;li&gt;Kalyani Bhatt&lt;br /&gt;     Center for Drug Evaluation and  Research&lt;br /&gt;     Food and Drug Administration&lt;br /&gt;     10903 New Hampshire  Avenue&lt;br /&gt;     WO31-2417&lt;br /&gt;     Silver Spring, Maryland 20993-0002&lt;br /&gt;     Phone:  301-796-9001&lt;br /&gt;     Fax: 301-847-8533&lt;br /&gt;     E-mail: &lt;a href="mailto:ACRHD@fda.hhs.gov"&gt;&lt;u&gt;&lt;font color="#0000ff"&gt;ACRHD@fda.hhs.gov&lt;/font&gt;&lt;/u&gt;&lt;/a&gt;&lt;/li&gt; &lt;/ul&gt; &lt;ul&gt;     &lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;     1-800-741-8138&lt;br /&gt;     (301-443-0572  in the Washington DC area)&lt;br /&gt;     Please call the Information Line for up-to-date information on this  meeting.&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.  Therefore, you should always check the agency&amp;rsquo;s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.&lt;/p&gt; &lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.  FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Kalyani Bhatt at (301) 796-9001 at least 7 days in advance of the meeting.&lt;/p&gt; &lt;p&gt;Information regarding ground  transportation, airport information, lodging, driving directions and  visitor parking, and security can be accessed at: &lt;a href="[!--$wcmUrl('link','UCM241740')--]" target=""&gt;Public Meetings at the FDA White Oak Campus.&lt;/a&gt;&lt;/p&gt; &lt;p&gt;FDA is committed to the orderly conduct of its  advisory committee meetings. Please visit our Web site at &lt;a href="[!--$wcmUrl('link','UCM111462')--]" target=""&gt;Public Conduct During FDA Advisory Committee  Meetings&lt;/a&gt; for  procedures on public conduct during advisory committee meetings.&lt;/p&gt; &lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5  U.S.C. app.2).&amp;nbsp;&amp;nbsp;&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
